The Latest News November 23, 2020 argenx Enters Into Agreement To Acquire Priority Review Voucher Breda, the Netherlands / Ghent, Belgium argenx today announced that the company has agreed to acquire a U.S. Food and Drug Administration (FDA) Priority Review Voucher (PRV) from Bayer Healthcare Pharmaceuticals, Inc for $98 million. Read argenx Enters Into Agreement To Acquire Priority Review Voucher More Press Releases News November 17, 2020 argenx Premieres A Mystery to Me, a Docuseries Inspired by the Myasthenia Gravis Patient Experience argenx today announced the release of a new docuseries, A Mystery to Me, which depicts the experiences of people living with myasthenia gravis (MG), a rare and often unpredictable, chronic autoimmune disease. Read News November 9, 2020 argenx to Participate in Upcoming Virtual Investor Conferences argenx today announced that management will participate in several upcoming investor conferences. Read News October 22, 2020 argenx Reports Third Quarter 2020 Financial Results and Provides Business Update argenx today announced its financial results for the third quarter ended September 30, 2020 and provided a business update. Read Media Center Publications ARGX-118 CIDP Cusatuzumab Efgartigimod Immune Thrombocytopenia Myasthenia Gravis Pemphigus Vulgaris SIMPLE Antibody Platform Facet Tags May 1, 2020 Making Asthma Crystal Clear April 16, 2020 Monoclonal antibodies against GARP/TGF-b1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo April 13, 2020 ARGX-116 / A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels April 8, 2020 Protein crystallization promotes type 2 immunity and is reversible by antibody treatment April 7, 2020 SIMPLE Antibody platform / Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy Load more
News November 17, 2020 argenx Premieres A Mystery to Me, a Docuseries Inspired by the Myasthenia Gravis Patient Experience argenx today announced the release of a new docuseries, A Mystery to Me, which depicts the experiences of people living with myasthenia gravis (MG), a rare and often unpredictable, chronic autoimmune disease. Read
News November 9, 2020 argenx to Participate in Upcoming Virtual Investor Conferences argenx today announced that management will participate in several upcoming investor conferences. Read
News October 22, 2020 argenx Reports Third Quarter 2020 Financial Results and Provides Business Update argenx today announced its financial results for the third quarter ended September 30, 2020 and provided a business update. Read
